Nobel Laureate Lecture Series

The University of Virginia was founded by Thomas Jefferson, a statesman, architect, farmer and  inventor. In the spirit of Jefferson, we would like to invite the world’s greatest thinkers and intellectuals to share their personal experiences and ideas with the UVA community.

Every fall, a Nobel Laureate Scholar will be invited to the University of Virginia, a UNESCO World Heritage Site, to speak to the community, and to meet one on one with students and faculty in their field. The visiting scholar will share their personal experiences in addressing the most challenging questions in their field, and their biggest and newest ideas. The purpose of the series is to motivate students and faculty to pursue excellence, increase researcher morale, and provide students with unique and valuable feedback on their work. The event will help enhance UVA’s global image as destination and a platform for great thinkers and ideas.

October 15, 2021: Phil Sharp

Lecture: A new biology: Convergence over the last decade and a vision for the future

11:30 AM - 12:30 PM - The Rotunda (download flyer) - Register for event

3:00 PM - 4:00 PM - Fireside chat with the Vice President for Research (South Meeting Room, Newcomb Hall) - (download flyer)Register for event

Phillip A. Sharp, Ph.D., Institute Professor
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

A world leader of research in molecular biology and biochemistry, Dr. Phillip A. Sharp is Institute Professor at the Massachusetts Institute of Technology.  

Much of Dr. Sharp's scientific work has been conducted at MIT's Center for Cancer Research (now the Koch Institute), which he joined in 1974 and directed from 1985 to 1991.  He subsequently led the Department of Biology from 1991 to 1999 before assuming the directorship of the McGovern Institute from 2000-2004.  His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing.  His landmark achievement was the discovery of RNA splicing in 1977.  This work provided one of the first indications of the startling phenomenon of “discontinuous genes” in mammalian cells.  The discovery that genes contain nonsense segments that are edited out by cells in the course of utilizing genetic information is important in understanding the genetic causes of cancer and other diseases. This discovery, which fundamentally changed scientists' understanding of the structure of genes, earned Dr. Sharp the 1993 Nobel Prize in Physiology or Medicine.  His lab has now turned its attention to understanding how RNA molecules act as switches to turn genes on and off (RNA interference).  These newly discovered processes have revolutionized cell biology and could potentially generate a new class of therapeutics.

Dr. Sharp has authored over 385 scientific papers.  He has received numerous awards and honorary degrees, and has served on many advisory boards for the government, academic institutions, scientific societies, and companies.  His awards include the Gairdner Foundation International Award, General Motors Research Foundation Alfred P. Sloan, Jr. Prize for Cancer Research, the Albert Lasker Basic Medical Research Award, the National Medal of Science and the inaugural Double Helix Medal from CSHL.  He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and is a Foreign Fellow of the Royal Society, UK.  

A native of Kentucky, Dr. Sharp earned a B.A. degree from Union College, KY in 1966, and a PhD in chemistry from the University of Illinois, Champaign-Urbana in 1969.  He did his postdoctoral training at the California Institute of Technology, where he studied the molecular biology of plasmids from bacteria in Professor Norman Davidson's laboratory.   Prior to joining MIT, he was Senior Scientist at Cold Spring Harbor Laboratory.

In 1978 Dr. Sharp co-founded Biogen (now Biogen Idec) and in 2002 he co-founded Alnylam Pharmaceuticals, an early-stage therapeutics company.

Phil Sharp